|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2250 GBX | -.--% |
|
+2.27% | - |
| 03-01 | Kanabo Group PLC Announces Termination Of Director Appointment of Sharon Malka, Effective February 27, 2026 | CI |
| 12-12 | Quantum Helium increases Sagebrush project interest | AN |
| Market Cap | 5.38M 7.17M 6.3M 5.86M 10.1M 691M 10.26M 69.56M 27.18M 340M 26.92M 26.34M 1.17B | P/E 2022 |
-1.15x | P/E 2023 | -1.88x |
|---|---|---|---|---|---|
| Enterprise Value | 2.44M 3.25M 2.86M 2.66M 4.58M 313M 4.65M 31.54M 12.32M 154M 12.21M 11.95M 532M | EV / Sales 2022 |
8.33x | EV / Sales 2023 | 16.5x |
| Free-Float |
93.73% | Yield 2022 * |
-
| Yield 2023 | - |
| 1 week | +2.27% | ||
| Current month | +2.27% | ||
| 1 month | +2.27% |
| Current year | 0.22 |  | 0.22 |
| 1 year | 0.22 | | 0.22 |
| 3 years | 0.15 | | 3.2 |
| 5 years | 0.15 | | 26 |
| 10 years | 0.15 | | 51 |
| Manager | Title | Age | Since |
|---|---|---|---|
Avihu Tamir
CEO | Chief Executive Officer | - | - |
Assaf Vardimon
DFI | Director of Finance/CFO | 48 | - |
Suleman Sacranie
CTO | Chief Tech/Sci/R&D Officer | 37 | - |
| Director | Title | Age | Since |
|---|---|---|---|
Avihu Tamir
BRD | Director/Board Member | - | - |
Sharon Malka
BRD | Director/Board Member | 53 | 2023-05-03 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 10/31/24 | Others | Chairman | 18,011,111 | 2.8479% | ||
| 10/29/24 | Free | Chairman | 17,361,111 | 2.7452% | ||
| 8/28/24 | Buy | Chief Technology Officer | 75,187 | 0.0119% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +2.27% | -.--% | -88.46% | 1.85M | |
| +0.86% | +1.43% | +48.50% | +160.39% | 1,057B | |
| +1.59% | +4.09% | +55.34% | +53.96% | 624B | |
| +0.95% | +1.91% | +35.91% | +81.14% | 454B | |
| +1.60% | +6.25% | +33.95% | +29.84% | 341B | |
| -0.60% | +1.52% | +35.68% | +39.76% | 297B | |
| -0.14% | +0.60% | +16.17% | +17.53% | 262B | |
| +0.09% | -2.82% | -28.29% | -41.71% | 215B | |
| +1.22% | +2.66% | +21.87% | +59.73% | 201B | |
| -1.18% | -3.70% | +14.23% | +66.51% | 162B | |
| Average | +0.33% | +0.13% | +23.34% | +37.87% | 361.4B | |
| Weighted average by Cap. | +0.54% | +1.92% | +35.73% | +77.61% |
| 2022 | 2023 | |
|---|---|---|
| Net sales | 603K 805K 707K 657K 1.13M 77.48M 1.15M 7.8M 3.05M 38.09M 3.02M 2.96M 132M | 895K 1.19M 1.05M 975K 1.68M 115M 1.71M 11.58M 4.52M 56.53M 4.48M 4.39M 195M |
| Net income | -6.87M -9.16M -8.05M -7.48M -12.9M -882M -13.1M -88.86M -34.72M -434M -34.39M -33.65M -1.5B | -7.99M -10.66M -9.36M -8.7M -15.01M -1.03B -15.24M -103M -40.38M -505M -40M -39.14M -1.74B |
| Net Debt | -3.01M -4.02M -3.53M -3.28M -5.66M -387M -5.75M -38.98M -15.23M -190M -15.09M -14.76M -658M | -2.94M -3.92M -3.44M -3.2M -5.52M -377M -5.61M -38.02M -14.85M -186M -14.72M -14.4M -642M |
Employees
20
Sector
Pharmaceuticals
- Stock Market
- Stocks
- KNB Stock
Select your edition
All financial news and data tailored to specific country editions
